Critical Outcome Tec (COTQF) 0.3060 $COTQF
Selective and Potent Anti-Cancer P53-Dependent Activity Demonstrated by Critical Outcome's COTI-2
Marketwire - Wed Sep 10, 8:07AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, has successfully completed additional and definitive testing confirming COTI-2's p53-dependent mechanism of action. The additional animal experiments were requested as part of Portage Biotech Inc.'s ("Portage" due diligence related to the non-binding letter of intent to form a joint venture previously announced on February 26, 2014.
Critical Outcome Technologies and UT MD Anderson Cancer Center Sign Letter of Intent for Phase 1 Development of COTI-2
Marketwire - Mon Sep 08, 8:05AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company" the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a letter of intent ("LOI" with The University of Texas MD Anderson Cancer Center in Houston ("MD Anderson" , for the Phase 1 clinical development of the Company's lead cancer drug candidate, COTI-2, in gynecological cancers.
Critical Outcome Technologies Reports Year-End Financial and Operating Results
Marketwire - Thu Jul 24, 3:21PM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF) reported its financial and operating results today for the fourth quarter and the year ended April 30, 2014 ("FYE 2014" .
Critical Outcome Technologies Inc. Announces Warrant Term Amendment
Marketwire - Wed Jul 16, 3:16PM CDT
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT)(OTCQB: COTQF) announced today that it is amending the expiry date of 3,569,458 common share purchase warrants (Warrants) issued as part of a non-brokered private placement on January 30, 2013, that were scheduled to expire on July 29, 2014. Each Warrant entitled its holder to purchase one common share of the Company at an exercise price of $0.26 per share for a period of 18 months from the date of issue.
Critical Outcome Technologies Seeks to Redefine Personalized Cancer Care With Project ROSALIND
Marketwire - Mon Jun 23, 8:05AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that Dr. Wayne Danter, President & CEO, will introduce "Project ROSALIND" in a podium presentation on June 25, 2014, at the annual BIO International Convention in San Diego California. The Company will use the hashtag #ROSALIND on Twitter for sharing more information with those not able to attend the presentation in person.
Critical Outcome Technologies Receives Orphan Drug Designation For COTI-2
Marketwire - Wed Jun 18, 1:30AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that the U.S. Food and Drug Administration (FDA) has granted COTI-2 an Orphan Drug Designation for the treatment of ovarian cancer.
Critical Outcome Technologies to Commence Trading in U.S. on OTCQB Under Symbol COTQF
Marketwire - Mon Jun 16, 8:03AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced that its common shares will commence trading today in the United States on the OTCQB venture stage marketplace under the symbol "COTQF."
Critical Outcome Technologies Inc.: SeeThruEquity Initiates Research Coverage
Marketwire - Fri Jun 13, 6:43PM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that SeeThruEquity, LLC ("SeeThruEquity" of New York, NY has initiated research coverage of COTI.
Critical Outcome Technologies Invited to Present at 16th International p53 Workshop in Sweden
Marketwire - Fri Jun 13, 8:01AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company" (TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, announced today that its President and CEO, Dr. Wayne Danter, will be a featured presenter at the 16th International p53 Workshop at the Stockholm Waterfront Congress Centre in Sweden, which runs from June 15-19, 2014. This annual conference brings together world-renowned scientists to discuss novel, basic, transitional, and clinical research in the area of cancer biology with a focus on the p53 tumor suppressor gene.
Critical Outcome Technologies Reports Third Quarter Results
Marketwire - Fri Mar 14, 8:02AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Company" , the bioinformatics and accelerated drug discovery company, reported its financial and operating results today for the three and nine month periods ended January 31, 2014.
Selective and Potent Anti-Cancer P53-Dependent Activity Demonstrated by Critical Outcome's COTI-2
Marketwire - Wed Sep 10, 8:07AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, has successfully completed additional and definitive testing confirming COTI-2's p53-dependent mechanism of action. The additional animal experiments were requested as part of Portage Biotech Inc.'s ("Portage" due diligence related to the non-binding letter of intent to form a joint venture previously announced on February 26, 2014. Critical Outcome Technologies and UT MD Anderson Cancer Center Sign Letter of Intent for Phase 1 Development of COTI-2
Marketwire - Mon Sep 08, 8:05AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT)(OTCQB: COTQF) ("COTI" or the "Company"
the bioinformatics and accelerated drug discovery company, is pleased to announce that it has signed a letter of intent ("LOI" with The University of Texas MD Anderson Cancer Center in Houston ("MD Anderson" , for the Phase 1 clinical development of the Company's lead cancer drug candidate, COTI-2, in gynecological cancers. Critical Outcome Technologies Reports Year-End Financial and Operating Results
Marketwire - Thu Jul 24, 3:21PM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF) reported its financial and operating results today for the fourth quarter and the year ended April 30, 2014 ("FYE 2014" . Critical Outcome Technologies Inc. Announces Warrant Term Amendment
Marketwire - Wed Jul 16, 3:16PM CDT
Critical Outcome Technologies Inc. (COTI) (TSX VENTURE: COT)(OTCQB: COTQF) announced today that it is amending the expiry date of 3,569,458 common share purchase warrants (Warrants) issued as part of a non-brokered private placement on January 30, 2013, that were scheduled to expire on July 29, 2014. Each Warrant entitled its holder to purchase one common share of the Company at an exercise price of $0.26 per share for a period of 18 months from the date of issue.
Critical Outcome Technologies Seeks to Redefine Personalized Cancer Care With Project ROSALIND
Marketwire - Mon Jun 23, 8:05AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that Dr. Wayne Danter, President & CEO, will introduce "Project ROSALIND" in a podium presentation on June 25, 2014, at the annual BIO International Convention in San Diego California. The Company will use the hashtag #ROSALIND on Twitter for sharing more information with those not able to attend the presentation in person. Critical Outcome Technologies Receives Orphan Drug Designation For COTI-2
Marketwire - Wed Jun 18, 1:30AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced today that the U.S. Food and Drug Administration (FDA) has granted COTI-2 an Orphan Drug Designation for the treatment of ovarian cancer. Critical Outcome Technologies to Commence Trading in U.S. on OTCQB Under Symbol COTQF
Marketwire - Mon Jun 16, 8:03AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT)(OTCQB: COTQF), the bioinformatics and accelerated drug discovery company, announced that its common shares will commence trading today in the United States on the OTCQB venture stage marketplace under the symbol "COTQF." Critical Outcome Technologies Inc.: SeeThruEquity Initiates Research Coverage
Marketwire - Fri Jun 13, 6:43PM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that SeeThruEquity, LLC ("SeeThruEquity" of New York, NY has initiated research coverage of COTI. Critical Outcome Technologies Invited to Present at 16th International p53 Workshop in Sweden
Marketwire - Fri Jun 13, 8:01AM CDT
Critical Outcome Technologies Inc. ("COTI" or the "Company"
(TSX VENTURE: COT), the bioinformatics and accelerated drug discovery company, announced today that its President and CEO, Dr. Wayne Danter, will be a featured presenter at the 16th International p53 Workshop at the Stockholm Waterfront Congress Centre in Sweden, which runs from June 15-19, 2014. This annual conference brings together world-renowned scientists to discuss novel, basic, transitional, and clinical research in the area of cancer biology with a focus on the p53 tumor suppressor gene. Critical Outcome Technologies Reports Third Quarter Results
Marketwire - Fri Mar 14, 8:02AM CDT
Critical Outcome Technologies Inc. (TSX VENTURE: COT) ("COTI" or the "Company"
, the bioinformatics and accelerated drug discovery company, reported its financial and operating results today for the three and nine month periods ended January 31, 2014. 
